Hilz, Max J. http://orcid.org/0000-0002-6802-1751
Roy, Sankanika
de Rojas Leal, Carmen
Liu, Mao
Canavese, Francesca
Winder, Klemens
Hoesl, Katharina M.
Lee, De-Hyung
Linker, Ralf A.
Wang, Ruihao
Funding for this research was provided by:
This study was financially supported by Novartis Pharma, Germany.
Article History
Received: 12 November 2020
Accepted: 15 December 2020
First Online: 14 January 2021
Compliance with ethical standards
:
: Dr. Hilz received compensation for activities with Sanofi Genzyme, Novartis Pharma, Bayer Health Care, Alnylam Pharmaceuticals, Amicus Therapeutics, and research support from Sanofi Genzyme, Bayer Health Care, and Novartis Pharma.Dr. Lee received compensation for activities with Alexion, Bayer, Biogen, Genzyme, Merck, Novartis and Roche.Dr. Linker received compensation for activities with Celgene, Biogen, Genzyme, Merck, Novartis, and Roche as well as research support from Biogen and Novartis.Drs. Roy, de Rojas Leal, Liu, Canavese, Winder, Hoesl, and Wang had no conflict of interest.
: The study was approved by the Ethics Committee of the University of Erlangen-Nuremberg and registered at the German Clinical Trial Register (DRKS00004548).
: After a detailed explanation of the study and all its procedures, all study participants gave their written informed consent according to the declaration of Helsinki.